Project Grant R03AR085677
- This Project Grant award for $300,000 from the Department of Health and Human Services' National Institutes of Health (CFDA 93.310 Trans-NIH Research Support) to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) supports research on the role of activated neutrophils and T cells in the pathogenesis of systemic lupus erythematosus (SLE), lupus nephritis, and vasculitis. The research aims to investigate how immune cell abnormalities, specifically the generation of...
- This $108,294 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient is The Medical University of South Carolina (MUSC), which will use the funding to identify novel glycomic biomarkers that can be detected in urine to monitor disease progression and predict treatment response in lupus nephritis, a serious kidney disease that affects...
- This $558,045 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate how the enzyme protein phosphatase 2A (PP2A) controls the function of T cells and contributes to the development of systemic lupus erythematosus (SLE). The research aims to determine how PP2A regulates metabolic enzymes involved in...
- This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $115,414 to the Beckman Research Institute of the City of Hope to conduct research aimed at concurrently eradicating pathogenic plasma cells and their precursors in systemic lupus erythematosus (SLE). The award, which runs from September 2024 to August 2026, will support two specific aims: 1) determining the effect of knockdown of the...
- This Project Grant award, valued at $199,130.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The objective is to demonstrate the clinical utility of patient-reported outcome measures (PROMs) in the care of individuals with advanced chronic kidney disease (CKD). The award will fund research across two key areas: 1) developing and validating risk...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $228,218 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct the "SGLT2I AS NOVEL GOUT CARE (SAVE-CARE): A RANDOMIZED CONTROLLED TRIAL". The project aims to evaluate the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) as a novel...
- This Project Grant award in the amount of $997,821.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research on the "Pathogenic Role of Neutrophil Subpopulations in Lupus Nephritis". The primary awardee is the Trustees of Dartmouth College, a prestigious private research university, with sub-awards going to The Johns Hopkins University and Dartmouth-Hitchcock Clinic to assist with the research. The grant...
- This Project Grant award of $405,350.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research aims to characterize lipid droplets in macrophage subsets and determine if manipulating lipid droplet content can shift macrophage function, with the goal of uncovering new therapeutic targets for systemic lupus erythematosus (SLE). The award recipient is The...
- This $802,363 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant will fund a research study at Emory University from September 2025 to June 2030 to develop models for predicting the benefits of GLP-1 receptor agonist (GLP-1RA) treatments in preventing obesity-related cardiometabolic diseases. The study aims to use clinical...
- This $793,093 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define the regulatory landscape of systemic lupus erythematosus (SLE) and its cardiovascular disease (CVD) comorbidity. The grantee, Oklahoma Medical Research Foundation, will conduct systematic, high-throughput studies in macrophages derived from induced pluripotent stem cells to identify genetic variants that disrupt regulatory...
This Project Grant award from the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $115,000.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the potential role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in improving cardiovascular and kidney outcomes for patients with Systemic Lupus Erythematosus (SLE) and Lupus Nephritis. The project aims to leverage large SLE cohorts to emulate target trials and test the hypothesis that GLP-1RA use will reduce the risk of major adverse cardiac events and kidney disease progression, including new-onset end-stage kidney disease, among patients with SLE and overweight/obesity. The project will also examine the association between GLP-1RA use and improvements in conventional cardiovascular risk factors in SLE patients. The award period is from Sep 15, 2025 to Jul 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 9/23/25 | ||
| Not listed | $115.0k | 9/8/25 |